Indian Pharmaceutical Alliance Defends Section 3(d) Of Patents Act, Says Statute Not Against Incremental Innovations
This article was originally published in PharmAsia News
Executive Summary
MUMBAI - The Indian Pharmaceutical Alliance - an influential lobbying group that represents 15 leading Indian drug makers - has stridently opposed a 2009 report published by the U.S.-India Business Council that called for certain changes in the country's Patents Act
You may also be interested in...
Despite Headwinds On Glivec, Novartis Gears Up To Bring Tasigna To India
MUMBAI - For many years Swiss pharmaceutical giant Novartis voiced reservations about certain provisions of the Indian patent laws and data exclusivity issues, but the maker of Glivec (imatinib) looks set to introduce its next-line therapy for chronic myeloid leukemia Tasigna (nilotinib) into the Indian market
Despite Headwinds On Glivec, Novartis Gears Up To Bring Tasigna To India
MUMBAI - For many years Swiss pharmaceutical giant Novartis voiced reservations about certain provisions of the Indian patent laws and data exclusivity issues, but the maker of Glivec (imatinib) looks set to introduce its next-line therapy for chronic myeloid leukemia Tasigna (nilotinib) into the Indian market
Novartis Suffers Setback As Indian Patent Appeals Board Strikes Down Glivec Patent
MUMBAI - Hopes for Novartis to obtain a product patent for its chronic myeloid leukemia drug Gleevec (imatinib) were dashed after India's Intellectual Property Appellate Board ruled that Novartis' patent application covering the medicine's beta-crystalline version is not patentable because it failed to satisfy the requirements under Section 3(d) of the India Patents Act